These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18756545)

  • 21. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report.
    Berger M; Ferrero I; Vassallo E; Gastaldo L; Carraro F; Biasin E; Madon E; Fagioli F
    Pediatr Hematol Oncol; 2005; 22(7):597-608. PubMed ID: 16166053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
    Schlenk RF; Benner A; Hartmann F; del Valle F; Weber C; Pralle H; Fischer JT; Gunzer U; Pezzutto A; Weber W; Grimminger W; Preiss J; Hensel M; Fröhling S; Döhner K; Haas R; Döhner H;
    Leukemia; 2003 Aug; 17(8):1521-8. PubMed ID: 12886238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.
    Thomas X; Boiron JM; Huguet F; Dombret H; Bradstock K; Vey N; Kovacsovics T; Delannoy A; Fegueux N; Fenaux P; Stamatoullas A; Vernant JP; Tournilhac O; Buzyn A; Reman O; Charrin C; Boucheix C; Gabert J; Lhéritier V; Fiere D
    J Clin Oncol; 2004 Oct; 22(20):4075-86. PubMed ID: 15353542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
    Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Sawada M; Goto N; Kitagawa J; Shimizu M; Oyama M; Moriwaki H
    Hematol Oncol; 2008 Mar; 26(1):33-8. PubMed ID: 17918772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
    Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
    Bone Marrow Transplant; 2004 Jun; 33(12):1201-8. PubMed ID: 15094745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
    He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M
    BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.
    Brandwein JM; Gupta V; Schuh AC; Schimmer AD; Yee K; Xu W; Messner HA; Lipton JH; Minden MD
    Am J Hematol; 2008 Jan; 83(1):54-8. PubMed ID: 17696207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete remission following donor PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous leukemia after allogeneic stem cell transplantation.
    Trenschel R; Bernier M; Stryckmans P; Verhest A; Badjou R; Crombez P; Bron D
    Bone Marrow Transplant; 1997 Feb; 19(4):381-3. PubMed ID: 9051249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.